The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | L | Antineoplastic and immunomodulating agents | |
2 | L04 | Immunosuppressants | |
3 | L04A | Immunosuppressants | |
4 | L04AB | Tumor necrosis factor alpha (TNF-α) inhibitors |
Code | Title | |
---|---|---|
L04AB01 | Etanercept | |
L04AB02 | Infliximab | |
L04AB03 | Afelimomab | |
L04AB04 | Adalimumab | |
L04AB05 | Certolizumab pegol | |
L04AB06 | Golimumab | |
L04AB07 |
Active Ingredient | Description | |
---|---|---|
Adalimumab |
Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). |
|
Afelimomab |
Afelimomab is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally. |
|
Certolizumab pegol |
Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation constant (KD) of 90 pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. Certolizumab pegol was shown to neutralise membrane associated and soluble human TNFα in a dose-dependent manner. By inhibiting the action of TNFα, certolizumab pegol reduces inflammation and other symptoms in patients with rheumatoid arthritis. |
|
Etanercept |
Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive. |
|
Golimumab |
Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNF-α, which prevents the binding of TNF-α to its receptors. |
|
Infliximab |
Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFβ). |
Title | Information Source | Document Type | |
---|---|---|---|
AVSOLA Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
Cimzia 200 mg solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CIMZIA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
ENBREL Powder for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
FLIXABI Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUKYNDRA 40mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUKYNDRA 80mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMIRA 20mg Solution for injection in pre-filled syringe | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMIRA 40mg/0.4ml Solution for injection in pre-filled syringe / pen | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMIRA 40mg/0.8ml Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMIRA 40mg/0.8ml Solution for injection in pre-filled syringe / pen | European Medicines Agency (EU) | MPI, EU: SmPC | |
HUMIRA 80mg Solution for injection in pre-filled syringe / pen | European Medicines Agency (EU) | MPI, EU: SmPC | |
IDACIO Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
INFLECTRA Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
LIBMYRIS 40 mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
LIBMYRIS 80 mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
RENFLEXIS Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
SIMPONI 50mg Solution for injection in pre-filled syringe / pen | European Medicines Agency (EU) | MPI, EU: SmPC | |
YUFLYMA 40 mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
ZESSLY Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |